European Biotech Leaders Say Optimism Is Returning

European biotech leaders say optimism is returning

Senior figures in European biopharma think dealmaking and M&A will increase in the region, and could be helped by US policy uncertainties.

BIO-Europe C-Suite Survey: Biopharma dealmaking set to accelerate, but investor caution still caps ambition

75% of biopharma leaders expect partnering and M&A appetite to increase over the next 12 months, none expect a decline 69% expect access to capital to improve, yet 79% identify investor risk aversion as the biggest constraint on biotech investment 52% say US policy uncertainty has made Europe more attractive to build and partner in, […]

Report: Europe’s biotech leaders see recovery, but investors remain the obstacle - European Biotechnology Magazine

Exclusive European data from BIO-Europe’s inaugural C-suite survey, shared with European Biotechnology, shows a sector expecting better funding conditions while struggling with investor caution. Among 69 executives at European-headquartered companies, 84% identify investor risk aversion as biotech investment’s biggest constraint, even as 70% expect their company’s access to capital to improve over the next year.